Table 3.
Univariate and Multivariate Analyses of the Relative Risk of Overall Survival After Propensity Score Matching
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Treatment (supportive vs chemotherapy*) | 0.504 (0.267–0.953) | 0.035 | 0.448 (0.225–0.894) | 0.023 |
| Age (year) (<60 vs ≥60) | 1.080 (0.584–1.999) | 0.806 | 1.341 (0.677–2.655) | 0.400 |
| Gender (female vs male) | 0.694 (0.357–1.349) | 0.281 | ||
| WBC (×109/L) (<13 vs ≥13) | 0.851 (0.459–1.578) | 0.609 | 1.449 (0.675–3.111) | 0.342 |
| Hb (g/L) (<60 vs ≥60) | 0.707 (0.343–1.459) | 0.348 | ||
| Albumin (g/L) (<30 vs ≥30) | 0.974 (0.443–2.141) | 0.947 | 1.205 (0.503–2.885) | 0.675 |
| Blast cell in PB (%) (<5 vs ≥5) | 1.087 (0.476–2.484) | 0.843 | ||
| Blast cell in BM (%) (<10 vs ≥10) | 0.806 (0.421–1.542) | 0.515 | ||
| Bone marrow dysplasia in smear (absent vs single/multi-lineage) | 1.702 (0.898–3.229) | 0.103 | 1.916 (0.945–3.882) | 0.071 |
| Megakaryocyte dysplasia (no vs yes) | 1.601 (0.847–3.028) | 0.148 | ||
| WHO (CMML-0 and CMML-1 vs CMML-2) | 0.820 (0.439–1.529) | 0.532 | ||
| Chromosome karyotype (normal vs abnormal) | 2.429 (1.225–4.818) | 0.011 | ||
| CPSS (low and intermediate-1 vs intermediate-2 andhigh) | 2.090 (1.051–4.158) | 0.036 | 3.399 (1.333–8.667) | 0.010 |
Notes: *Chemotherapy group included patients underwent Hematopoietic Stem Cell Transplantation (HSCT).